Cited by 65Gastrointestinal motility and disordersPelvic floor disorders treatmentsGastroesophageal reflux and treatments

Use of prucalopride for chronic constipation: a systematic review and meta-analysis of published randomized, controlled trials

Open access
Sajid, Muhammad S, Hebbar, Madhu, Baig, Mirza K, Li, Andy, Philipose, Zinu·2016·Journal of Neurogastroenterology and Motility

Abstract

This article highlights the role of prucalopride in the management of chronic constipation based upon the principles of meta-analysis using data reported in the published randomized, controlled trials. Sixteen randomized, controlled trials on 3943 patients reported the effectiveness of prucalopride in patients with chronic constipation. Prucalopride successfully increased the frequency of spontaneous bowel movements per week in all variable doses of 1 mg (standardized mean difference [SMD], 0.42 [95% CI, 0.18-0.66; P = 0.006]), 2 mg (SMD, 0.34 [95% CI, 0.11-0.56; P = 0.003]), and 4 mg (SMD, 0.33 [95% CI, 0.22-0.44; P = 0.00001]). The risks of adverse events or side effects such as headache, abdominal cramps, excessive flatulence, dizziness, diarrhea, and rash were higher (odds ratio, 1.70 [95% CI, 1.27 to -2.27; P = 0.0004]) in prucalopride group. Prucalopride is clinically a beneficial pharmacotherapy for chronic constipation and its routine use may be considered in patients with chronic simple laxative-resistant constipation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5056/jnm16004

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Prucalopride, a highly selective agonist for the serotonin 5-HT4 receptor, increases the number of bowel movements per week in adults with chronic functional constipation.

    “For example, prucalopride, a highly selective agonist for serotonin 5-HT4 receptor, increases the number of bowel movements per week in adults with chronic FC [ 64 ].”

    From Role of gut microbiota in functional constipation (2021) · cites this paper as [64]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 1

  1. [34]Review Manager (Rev Man) [Computer program]. Version 5.0 The Nordic Cochrane Centre, The Cochrane Collaboration Copenhagen 2008 Available from URL: http://tech.cochrane.org/revman/download/windows64 accessed 21 April 2016

Cited by

Sorted by citations

Authors
Sajid, M. S., Hebbar, M., Baig, M. K., Li, A., & Philipose, Z.
Affiliations
  • Worthing Hospital (GB)
  • National Health Service (GB)
Corresponding author
Sajid, Muhammad S
Venue
Journal of Neurogastroenterology and Motility
Published
2016-06-28
Volume
22
Issue
3
Pages
412-422
ISSN
  • 2093-0879 (ISSN-L)
  • 2093-0887
OpenAlex
W2343386012
Cited by
65
References
70
Citations by year
2026: 2 · 2025: 8 · 2024: 7 · 2023: 8 · 2022: 5 · 2021: 10 · 2020: 2 · 2019: 8 · 2018: 8 · 2017: 6 · 2016: 1
FWCI
1.28
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Journal of Neurogastroenterology and Motility (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Rheumatology › Pelvic floor disorders treatments
  • Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
Keywords
prucalopride, chronic constipation, stool frequency, adverse events, drug efficacy, serotonin receptor agonists, pharmacotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review